Nouscom's $135M Series D: A Cancer Vaccine That Could Stop Tumors Before They Start

Jan de Vries · 2026-10-19

Nouscom, a Basel-based biotech company, just closed an oversubscribed $135 million (€120 million) Series D round. That's a big number for any startup, but what makes this one interesting is what they're trying to do: stop cancer before it even gets a chance to grow. ### A Different Kind of Cancer Treatment Most cancer therapies focus on treating tumors after they've formed. Nouscom is flipping that idea on its head. Their lead program, NOUS-209, is an off-the-shelf immunotherapy designed for people with Lynch Syndrome (LS) — a genetic condition that gives carriers up to an 80% lifetime risk of cancer. Right now, these folks have two options: constant surveillance or surgery. That's it. "Over two million LS carriers live with up to an 80% lifetime cancer risk and nothing to offer them but surveillance and surgery," says Marina Udier, Ph.D., CEO of Nouscom. "We built Nouscom to change that equation." The company's approach uses a viral vector platform to deliver optimized neoantigens — basically, it trains the immune system to recognize and attack cancer cells early on. Think of it as a vaccine that teaches your body what to look for before the enemy even shows up. ### The Money and the Mission The round was co-led by M Ventures and Revelation Partners, with new investors like Angelini Ventures, the EIB, and Neva SGR joining in. Existing backers — 5AM Ventures, Andera Partners, Bpifrance, CDP Venture Capital, EQT Life Sciences, and others — all participated. That kind of continued support from existing investors says a lot about their confidence in the science. Dr. Hakan Goker, Managing Director at M Ventures, put it this way: "What sets Nouscom apart is its unique cancer interception approach and the platform that enables it. Maturing clinical evidence and a regulatory-aligned path into a registration-enabling trial in such an unchartered space is a rare combination for a private biotech company." In other words, they're not just playing with ideas — they've got data and a clear path forward. ### A Wave of European Oncology Funding Nouscom's raise isn't happening in a vacuum. It's part of a broader trend of European oncology startups pulling in serious cash. In 2026 alone, we've seen: - ErVimmune (France) raise $19 million for its off-the-shelf cancer vaccine - Brenus Pharma (France) secure $12 million for immunotherapy development - Kupando (Germany) add $11 million - STORM Therapeutics (UK) raise $53 million - Engitix (UK) secure $23 million - Moonlight AI (Switzerland) raise $3 million for cancer diagnostics Add those up and you get roughly $122 million — and that's before Nouscom's $135 million. Together, we're talking about over $250 million flowing into European cancer research. That's not pocket change. ### What's Next for Nouscom? The new funds will push NOUS-209 through a single, global, registration-enabling clinical trial for cancer interception in Lynch Syndrome carriers. If successful, this could be the first therapy specifically approved to prevent cancer in high-risk populations. Nouscom was founded in 2015 and has been quietly building its platform ever since. Their pipeline also includes NOUS-PEV, a personalized neoantigen immunotherapy that completed a Phase 1b trial with published data. So they're not a one-trick pony. For those of us watching the European startup scene, Nouscom's story is a reminder that deep tech and biotech can attract big money when the science is solid and the mission is compelling. And for patients with Lynch Syndrome, it might just be the breakthrough they've been waiting for.